WO2016059624A3 - Compositions and methods for treatment of diseases - Google Patents

Compositions and methods for treatment of diseases Download PDF

Info

Publication number
WO2016059624A3
WO2016059624A3 PCT/IE2015/000014 IE2015000014W WO2016059624A3 WO 2016059624 A3 WO2016059624 A3 WO 2016059624A3 IE 2015000014 W IE2015000014 W IE 2015000014W WO 2016059624 A3 WO2016059624 A3 WO 2016059624A3
Authority
WO
WIPO (PCT)
Prior art keywords
camelid
inhibitor
equine
compositions
ungulate
Prior art date
Application number
PCT/IE2015/000014
Other languages
French (fr)
Other versions
WO2016059624A2 (en
Inventor
Patrick T. Prendergast
Original Assignee
Prendergast Patrick T
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IE20140274A external-priority patent/IE20140274A1/en
Priority claimed from IE20150270A external-priority patent/IE20150270A1/en
Application filed by Prendergast Patrick T filed Critical Prendergast Patrick T
Priority to EP20204479.8A priority Critical patent/EP3797786A1/en
Priority to US15/538,203 priority patent/US20180186864A1/en
Priority to EP15813581.4A priority patent/EP3207054A2/en
Priority to AU2015332002A priority patent/AU2015332002B2/en
Publication of WO2016059624A2 publication Critical patent/WO2016059624A2/en
Publication of WO2016059624A3 publication Critical patent/WO2016059624A3/en
Priority to US16/575,253 priority patent/US20200031907A1/en
Priority to AU2021209220A priority patent/AU2021209220A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method for treating or preventing laminitis is provided comprising administering to an ungulate a therapeutically or prophylactically effective amount of a camelid protease inhibitor. Typically the ungulate is a horse and the camelid protease inhibitor is an inhibitor of equine metalloproteinases and equine serine proteases. The inhibitor may be isolated from blood from healthy camelid or may be generated by inoculating camelid with purified equine metalloproteinase enzymes and serine proteases or with snake venom metalloproteinases, such as those obtained from Bothrops jararaca. The inhibitor may a homodimer antibody or an antigen binding fragment of same. Also provided are compositions comprising such camelid protease inhibitors.
PCT/IE2015/000014 2014-10-15 2015-10-14 Compositions and methods for treatment of diseases WO2016059624A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP20204479.8A EP3797786A1 (en) 2014-10-15 2015-10-14 Compositions and methods for treatment of diseases
US15/538,203 US20180186864A1 (en) 2014-10-15 2015-10-14 Compositions and methods for treatment of diseases
EP15813581.4A EP3207054A2 (en) 2014-10-15 2015-10-14 Compositions and methods for treatment of diseases
AU2015332002A AU2015332002B2 (en) 2014-10-15 2015-10-14 Compositions and methods for treatment of diseases
US16/575,253 US20200031907A1 (en) 2014-10-15 2019-09-18 Compositions and methods for treatment of diseases
AU2021209220A AU2021209220A1 (en) 2014-10-15 2021-07-27 Compositions And Methods For Treatment Of Diseases

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
IE20140274A IE20140274A1 (en) 2014-10-15 2014-10-15 Camelid blood serum or plasma and generated enzyme inhibitory homodimer antibodies their peptide isolates and/or synthetic peptide sequences for laminitis prevention and treatment and the treatment of other equine diseases created due to elevated metalloprotease and elastase (serine protease) enzyme activity.
IE2014/0274 2014-10-15
IE2015/0034 2015-01-13
IE20150034A IE20150034A1 (en) 2014-10-15 2015-01-13 Laminitis prevention and treatment through camelid serum
IE20150183 2015-06-18
IE2015/0183 2015-06-18
IE20150270A IE20150270A1 (en) 2015-08-17 2015-08-17 Compositions and methods for treatment of diseases
IE2015/0270 2015-08-17

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/538,203 A-371-Of-International US20180186864A1 (en) 2014-10-15 2015-10-14 Compositions and methods for treatment of diseases
US16/575,253 Division US20200031907A1 (en) 2014-10-15 2019-09-18 Compositions and methods for treatment of diseases

Publications (2)

Publication Number Publication Date
WO2016059624A2 WO2016059624A2 (en) 2016-04-21
WO2016059624A3 true WO2016059624A3 (en) 2016-10-06

Family

ID=54937333

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IE2015/000014 WO2016059624A2 (en) 2014-10-15 2015-10-14 Compositions and methods for treatment of diseases

Country Status (1)

Country Link
WO (1) WO2016059624A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106308817B (en) * 2016-08-12 2023-07-28 玉溪九洲生物技术有限责任公司 Horse plasma collection system

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2424370A (en) * 2005-03-21 2006-09-27 Mars Uk Ltd Treatment of Laminitis
WO2007011674A2 (en) * 2005-07-15 2007-01-25 Baker Donald J Compositions and methods for treating and preventing inflammatory and/or degenerative processes in humans and other animals
WO2008074840A2 (en) * 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576297A (en) 1993-05-10 1996-11-19 Lipps; Binie V. Embodiments of natural and synthetic lethal toxin neutralizing factors and their utility as treatment for envenomation
EP2424527B8 (en) 2009-04-29 2019-07-17 Willowcraft Pharm Inc. Mast cell stabilizers to prevent or treat laminitis
EP2497475A1 (en) 2011-03-09 2012-09-12 Sabine Dussler Treatment of laminitis with platelet aggregation inhibitors
US9402382B2 (en) 2012-05-04 2016-08-02 Michelle Burr Equine boot for treatment of laminitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2424370A (en) * 2005-03-21 2006-09-27 Mars Uk Ltd Treatment of Laminitis
WO2007011674A2 (en) * 2005-07-15 2007-01-25 Baker Donald J Compositions and methods for treating and preventing inflammatory and/or degenerative processes in humans and other animals
WO2008074840A2 (en) * 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CLUTTERBUCK A L ET AL: "Matrix metalloproteinases in inflammatory pathologies of the horse", VETERINARY JOURNAL, BAILLIERE TINDALL, LONDON, GB, vol. 183, no. 1, 1 January 2010 (2010-01-01), pages 27 - 38, XP026807342, ISSN: 1090-0233, [retrieved on 20081120] *
DE LA REBIERE DE POUYADE G ET AL: "Equine neutrophil elastase in plasma, laminar tissue, and skin of horses administered black walnut heartwood extract", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, ELSEVIER BV, AMSTERDAM, NL, vol. 135, no. 3-4, 15 June 2010 (2010-06-15), pages 181 - 187, XP027037865, ISSN: 0165-2427, [retrieved on 20091029], DOI: 10.1016/J.VETIMM.2009.10.024 *
FUGLER L A ET AL: "Clinical and Matrix Metalloproteinase Inhibitory Effects of Pentoxifylline on Carbohydrate Overload Laminitis: Preliminary Results", JOURNAL OF EQUINE VETERINARY SCIENCE, JONES, WILDOMAR, CA, US, vol. 30, no. 2, 1 February 2010 (2010-02-01), pages 106 - 107, XP026976404, ISSN: 0737-0806, [retrieved on 20100201] *
LOFTUS J P ET AL: "Leukocyte-derived and endogenous matrix metalloproteinases in the lamellae of horses with naturally acquired and experimentally induced laminitis", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, ELSEVIER BV, AMSTERDAM, NL, vol. 129, no. 3-4, 15 June 2009 (2009-06-15), pages 221 - 230, XP026018787, ISSN: 0165-2427, [retrieved on 20081107], DOI: 10.1016/J.VETIMM.2008.11.003 *
MARK J I PAINE ET AL: "Molecular Purification, Cloning, and Molecular Characterization of a High Molecular Weight Hemorrhagic Metalloprotease, Jararhagin, from Bothrops jararaca Venom", 15 November 1992 (1992-11-15), pages 22869 - 22876, XP055278594, Retrieved from the Internet <URL:http://www.jbc.org/content/267/32/22869.full.pdf> *
POLLITT C C ET AL: "BATIMASTAT (BB-94) INHIBITS MATRIX OF METALLOPROTEINASES OF EQUINE LAMINITIS", EQUINE VETERINARY JOURNAL, R & W PUBLICATIONS, SUFFOLK, GB, no. SUPPL. 26, 1 September 1998 (1998-09-01), pages 119 - 124, XP008065363, ISSN: 0425-1644 *
See also references of EP3207054A2 *
SOICHI TAKEDA ET AL: "Snake venom metalloproteinases: Structure, function and relevance to the mammalian ADAM/ADAMTS family proteins", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, ELSEVIER, NETHERLANDS, vol. 1824, no. 1, 11 April 2011 (2011-04-11), pages 164 - 176, XP028336054, ISSN: 1570-9639, [retrieved on 20110420], DOI: 10.1016/J.BBAPAP.2011.04.009 *
WU YAN ET AL: "Structural insight into distinct mechanisms of protease inhibition by antibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 104, no. 50, 11 December 2007 (2007-12-11), pages 19784 - 19789, XP009141928, ISSN: 0027-8424, DOI: 10.1073/PNAS.0708251104 *

Also Published As

Publication number Publication date
WO2016059624A2 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
MX2017003624A (en) Pyrazolyl-substituted pyridone compounds as serine protease inhibitors.
EA202091709A1 (en) DNA PC INHIBITORS
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer&#39;s disease
MX2022007376A (en) Fluoroalkyl-oxadiazoles and uses thereof.
EA201891539A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
EA201491151A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
EA201390711A1 (en) HYDROXYAMIDE COMPOUNDS OF Pyrimidine As Inhibitors of Protein Deacetylases and Methods for Their Use
MX2019002978A (en) Compositions comprising a non-pathogenic bacteria and methods for protecting plant and animal hosts from fungal, bacterial and viral diseases.
EA201790817A1 (en) 2-AMINO-3,5-DIFTOR-3,6-DIMETHYL-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS FOR THE TREATMENT OF ALLZHEIMER&#39;S DISEASE
EA201691558A1 (en) REMOVAL OF SERIN PROTEAS BY TREATMENT WITH Finely SILICENED SILICON DIOXIDE
MY182271A (en) Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
EA201490030A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
EA201690007A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
AU2012332832A8 (en) Compositions useful for the treatment of viral diseases
SG10201907699YA (en) Substituted pyrazole compounds as serine protease inhibitors
EA201791030A1 (en) 2-AMINO-5,5-DIFTOR-6- (FTORMETYL) -6-PHENYL-3,4,5,6-TETRAGIDPROPYRIDINES AS BACE1 INHIBITORS
MX2022012386A (en) Metalloenzyme inhibitor compounds.
EA201890878A1 (en) METHOD OF TREATMENT OF MEDDALLOBLASTOMES USING EZH2 INHIBITOR
MX2019001011A (en) Pharmaceutical compounds.
EA202091708A1 (en) DNA PC INHIBITORS
EA201891468A1 (en) COMPOSITIONS AND METHODS TO REDUCE TAU EXPRESSION
EA202091731A1 (en) AUTOTAXIN INHIBITORS AND THEIR APPLICATIONS
MA38296B2 (en) Selective nox-1 inhibitor peptides and their uses
EA201792610A1 (en) METHOD OF TREATMENT OF NEUROLOGICAL DISEASE
EA201700217A1 (en) METHOD OF CLEANING FOR ISOLATION AND COMMERCIAL PRODUCTION OF RECOMBINANT TNK-TPA

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15813581

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015813581

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015332002

Country of ref document: AU

Date of ref document: 20151014

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15813581

Country of ref document: EP

Kind code of ref document: A2